In March 2009, Merit Medical Systems, Inc. acquired the products formerly manufactured and distributed by Alveolus, Inc. This acquisition introduces a new division, Merit Endotek™, which integrates non-vascular stent technology with inflation devices, guide wires, and other accessories used throughout the medical community. Prior to the acquisition by Merit, Alveolus developed next-generation stent technology for use in the airway (AERO®), esophagus (ALIMAXX-ES®), and biliary tract (ALIMAXX-B®) to build value and quality in the creation of interventional and palliative treatment alternatives.
Since the very beginning, Merit Endotek has focused on expanding the boundaries of interventional and palliative medicine. This started with ALIMAXX-ES, the world’s first FDA cleared, fully covered esophageal stent. It includes AERO, a uniquely trusted and capable tracheobronchial stent. And it features a long list of other groundbreaking products—from the revolutionary BIG60 inflation device for pulmonary and gastroenterology balloon dilation to a complete family of integrated guide wires, negative pressure syringes, bipolar probes, and other solutions.
Today, Merit Endotek continues to expand this legacy of innovation and quality with a sharp focus on creative problem solving, a passion for listening and responding to our customers, and a commitment to developing groundbreaking new technology that enables clinicians to achieve the best possible clinical outcomes for their patients.
This approach has led to the launch of six innovative and successful new products since 2009. And it will allow us to continue to push the boundaries of innovation and performance for our customers in the years to come.
David Hamilton joined Merit Medical Endotek in June 2009 following the acquisition of Alveolus, Inc., a provider of non-vascular stent technology. As a Director, Hamilton was responsible for Endotek’s EMEA sales and marketing initiatives and worked closely with the US Sales and management team on operational, contractual, and strategic matters. In 2014, Hamilton became Vice President, Sales, and in 2017, he was promoted to the Executive VP of Sales & Marketing. In June 2018, Hamilton was promoted to his current position of Division President for Endotek. Prior to joining Alveolus, Hamilton was a lawyer working in Scotland.
Since joining Merit Medical in 2010, Barton Gill has held several product management roles of increasing responsibility within Merit’s Endotek division, where he has contributed to the development of the division’s gastrointestinal and pulmonary portfolios. In 2015 Gill was promoted to Sr. Director, Marketing for Merit’s Peripheral Intervention Division where he led upstream and downstream marketing efforts for that division. In 2017 Gill was promoted to his current role, Vice President of Sales, Endotek division. In this role, he is responsible for promoting customer satisfaction and sales growth. He holds a B.S. in Marketing and an M.B.A. from Westminster College.
Patrick MacCarthy joined Merit Medical Endotek in April 2018, after a business collaboration between NinePoint Medical and Merit Medical was forged. MacCarthy has more than 15 years of marketing and sales expertise within the medical device and technology sectors. In 2012, MacCarthy was the first commercial employee with NinePoint Medical, in the role of VP Marketing. He added Clinical Affairs responsibilities following the launch of NvisionVLE® Imaging System in the US. Prior to NinePoint Medical, MacCarthy was with Olympus America, Inc. In his current role, MacCarthy is responsible for domestic and international marketing initiatives as well as strategy, promotion and sales support. He holds a BS in Mechanical Engineering from Colorado School of Mines.